Angel Physicians Fund

Alphyn Biologics is a life science company that develops proprietary drug therapy for treating skin diseases. Alphyn's initial target indication are skin infections caused by deadly drug-resistant MRSA bacteria based on their proprietary Multi-Target Therapeutic (MTT) plant-derived technology platform.

PanTher Therapeutics is on a mission to revolutionize cancer care with a proprietary treatment platform designed to enhance therapeutic response with minimal side effects. PanTher’s highly adaptable platform empowers oncologists to treat patients with life-threatening cancer by unlocking a drug’s full potential through direct, sustained treatment at the tumor site. This distinctive targeting capability uniquely positions PanTher to take on the deadliest and most difficult to treat cancers with a lead investigational candidate in pancreatic cancer.

Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

Sotera is a medical device company that focuses on innovative solutions for cardiac procedures. The company’s initial product is a solution for reducing complications to the esophagus during catheter ablation treatment for atrial fibrillation. It is commercializing a novel medical device designed to protect the esophagus during catheter ablation procedures.

Moray Medical develops a structural heart robotic delivery systems for edge-to-edge valve leaflet repair. Moray Medical is working to improve the quality of life for the millions suffering from leaky heart valves. Using our proprietary microfluidic robotics, more cardiologists can safely and cost-effectively treat the large number of patients who need mitral valve clip therapies.

Foldax is developing synthetic heart valves with the goal of delivering non-thrombogenic aortic and mitral valves at dramatically lower costs to existing artificial or tissue valves. It operates in the manufacturing sector. The company was incorporated in 2013 and is based in Salt Lake City, Utah.